Intelligence · Patents
Patents expiring in 2041
Annual patent cliff calendar for 2041 — US pharmaceutical patents by expiration date.
- Patents
- 2,000
Quick answer
2,000 indexed pharmaceutical patents have expiration dates in 2041. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 11202831
Solid solution compositions and use in cardiovascular disease
granted -
US 11202804
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
granted -
US 11202784
Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
granted -
US 11203749
Factor VII polypeptides that are modified and uses thereof
granted -
US 11202825
Attenuated infectious bronchitis virus
granted -
US 11202770
Liquid tasimelteon formulations and methods of use thereof
granted -
US 11202803
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
granted -
US 11202776
Treatment of gastroparesis with triazaspiro[4.5]decanone
granted -
US 11203756
Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
granted -
US 11202801
Notch receptors with hinge domain
granted -
US 11202787
Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
granted -
US 11202789
Method of treating glycogen storage disease
granted -
AR 119500
DERIVADOS DE 1,2,4-OXADIAZOL-5-ONA PARA EL TRATAMIENTO DEL CÁNCER
granted -
US 11207283
Inactivators of toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria
granted -
US 11208411
Compositions and methods for treating parasitic diseases
granted -
US 11207329
Methods for treating GI syndrome and graft versus host disease
granted -
US 11208397
Small molecule antagonists of sumo related modification of CRMP2 and uses thereof
granted -
US 11207361
AAV mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity
granted -
US 11208655
Functionally-modified oligonucleotides and subunits thereof
granted -
US 11208432
Inhibitors of glucocorticoid receptor
granted -
US 11208405
Pyrrole derivatives as PLK1 inhibitors
granted -
US 11207394
Anti-mutated KRAS T cell receptors
granted -
US 11207339
Targeted cancer therapy
granted -
US 11207315
Emetine compounds for treatment and prevention of flavivirus infection
granted -
US 11207270
Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
granted -
US 11207379
Peptides with anti-cancer activity
granted -
US 11207333
Compositions comprising triterpenoids and uses thereof for treating optic neuropathy
granted -
US 11207342
High density lipoprotein binding protein (Hdlbp/Vigilin) iRNA compositions and methods of use thereof
granted -
US 11207351
Materials and methods for engineering cells and uses thereof in immuno-oncology
granted -
US 11207356
Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
granted -
US 11207395
Infectious plasmodium sporozoites grown in vitro
granted -
US 11207423
Nanocarriers having surface conjugated peptides and uses thereof for sustained local release of drugs
granted -
US 11207396
Immunization to protect against adverse cardiac events relating to pneumococcal infection
granted -
US 11207429
Method and compositions for orally administered contrast agents for MR imaging
granted -
US 11207687
Artificial cells
granted -
US 11208385
N-substituted imidazole carboxylate compound, preparation method and use
granted -
US 11208330
Identification and optimization of carbon radicals on hydrated graphene oxide for ubiquitous antibacterial coatings
granted -
US 11208662
RNAi inhibition of alpha-ENaC expression
granted -
US 11208650
Modulators of IRF5 expression
granted -
US 11208640
Modulating human Cas9-specific host immune response
granted -
US 11208493
Internalizing human monoclonal antibodies targeting prostate and other cancer cells
granted -
US 11208479
CX43 hemichannel antibodies and methods of use
granted -
US 11208470
DNA antibody constructs and method of using same
granted -
US 11208456
Anti-KRAS-G12D T cell receptors
granted -
US 11208634
Deimmunized therapeutic compositions and methods
granted -
US 11208458
Compositions and methods for internalizing enzymes
granted -
US 11208416
Selective inhibitors of protein arginine methytransterase 5 (PRMT5)
granted -
US 11208413
Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
granted
Frequently asked questions
How many pharma patents expire in 2041?
2,000 published patents in our USPTO index have expiration dates falling in calendar year 2041.